Half-dose COVID boosters work as well as full doses in 601-adult, 12-month human trial
This week brought major advances in mRNA vaccine technologyโfrom proving that half-dose COVID boosters are just as effective as full doses, to engineering new lipid nanoparticles that dramatically improve where vaccines go in the body.
๐งฌ Half-Dose COVID Boosters Pack Same Punch as Full Doses
601 adults in Mongolia got either 15 ฮผg (half) or 30 ฮผg (full) doses of Pfizer's COVID booster after being primed with other vaccines like AstraZeneca
After 12 months, both doses showed comparable immune responses and safety profiles, with only slightly lower antibody levels in the half-dose group for some participants
25 documented COVID infections occurred (12 in half-dose, 13 in full-dose groups), plus 228 undocumented infections detected through antibody increases
Why it matters: Half-dose boosters could make vaccines more tolerable (fewer side effects) while stretching global vaccine supplies without sacrificing protection.
Key Findings
๐ฏ New Lipid Particles Target Spleen 4.5x Better Than Liver
Researchers replaced cholesterol and PEG in standard lipid nanoparticles with zwitterionic compounds, creating "ThrCo" particles
These new particles showed ~70% lower liver accumulation and 4.5-fold increase in spleen-specific mRNA translation compared to Pfizer-BioNTech formulations
The spleen targeting could boost vaccine responses since it's a key immune organ where antigen-presenting cells reside
๐ก Manganese Doubles mRNA Loading in Vaccine Particles
Scientists used manganese ions to create high-density mRNA cores, then coated them with lipids to form L@Mn-mRNA particles
This approach achieved nearly twice the mRNA loading capacity compared to conventional formulations while improving cellular uptake by 2-fold
The enhanced stiffness from the manganese-mRNA core contributed to better cellular uptake and stronger immune responses
๐ฌ mRNA Flu Vaccines Crush Traditional Shots in Older Adults
Meta-analysis of 7 trials with 7,114 participants aged โฅ65 compared mRNA flu vaccines to standard inactivated vaccines
mRNA vaccines achieved 3-4x higher seroconversion rates across all four seasonal flu strains (risk ratios ranging from 2.83 to 3.54)
The dramatic improvement addresses a key problem: conventional flu vaccines often work poorly in older adults whose immune systems are weaker
๐งช Nasal mRNA Vaccines Generate Powerful Lung Protection
Researchers optimized lipid formulations (F4 and F12) specifically for intranasal delivery, achieving significantly better mRNA delivery to nose and lungs
Intranasal F4-mRNA vaccine induced strong mucosal antibodies (IgA) in nose and lungsโthe first line of defense against respiratory viruses
This approach could prevent infection at the source rather than just preventing severe disease after infection occurs
๐ฏ AI Optimizes mRNA Sequences for 200% Better Protein Production
Scientists developed UTailoR, an AI system that redesigns the 5' UTR sequences (the "instruction manual" part of mRNA) to boost translation
The AI-optimized sequences produced ~200% more protein compared to original sequences in experimental tests
The system uses machine learning to predict which sequence changes will improve efficiency while keeping sequences close to the originals
๐ Three-Chain Lipids Outperform Standard Designs for Drug Delivery
Researchers tested 18 different lipid designs with 2-4 alkyl chains and found three-chain lipids were most effective at delivering drugs into cells
Three-chain lipids adopt a cone shape that promotes formation of inverted hexagonal phases, which helps disrupt endosomal membranes
Molecular simulations confirmed that the precise number of chains mattersโmore isn't always better for cellular uptake
Implications
These advances collectively point toward more efficient, targeted, and effective mRNA medicines. From AI-optimized sequences to precision-engineered delivery vehicles, the technology is rapidly maturing beyond the first-generation COVID vaccines toward more sophisticated therapeutic applications.
Studies in this issue
Primary sources used for this newsletter.
- Improved nasal nanoparticle formula boosts immune response of mRNA RSV vaccineskey findingNanoscale2025-10-10PMID 41071038
- Improving mRNA vaccines with fewer fats for better effectivenesskey findingNature communications2025-10-07PMID 41057328
- Using special ionizable lipids instead of cholesterol and PEGylated lipids in lipid nanoparticles to target mRNA delivery to the spleenkey findingScience advances2025-10-08PMID 41061074
- Improving protein-making from mRNA by using artificial intelligence to optimize starting RNA sequenceskey findingiScience2025-10-10PMID 41069846
- Shape of Charged Lipids Controls How They Break Down Cell Membranes Inside Cellskey findingJournal of the American Chemical Society2025-10-10PMID 41069017
- Antibody responses to mRNA flu vaccines in older adultskey findingAnnals of Saudi Medicine2025-10-06PMID 41047808
Continue reading
All mRNA Technology issuesGet the next mRNA Technology issue
Seven papers, once a week. Free.